Induction of ROS-mediated cell death and activation of the JNK pathway by a sulfonamide derivative

REHAN AHMAD1, MANSOOR-ALI VAALI-MOHAMMED1, MOHAMMED ELWATIDY2, OMAR AL-OBEED3, KHAVAL AL-KHAVAL1, WAGDY M. ELDEHNA3, HATEM A. ABDEL-IZIZ4, AHMED ALFAEFY5 and MAHA ABDULLA1

1Colorectal Research Chair, Department of Surgery, King Khaled University Hospital, College of Medicine, King Saud University; 2CMRC, College of Medicine, King Saud University, Riyadh 11472, Saudi Arabia; 3Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh 33511; 4Department of Applied Organic Chemistry, National Research Center, Cairo 12622, Egypt; 5Department of Chemistry, Kulliyyah of Science, International Islamic University, Kuantan 25200, Malaysia

Received December 20, 2018; Accepted May 23, 2019

DOI: 10.3892/ijmm.2019.4284

Abstract. The emergence of colorectal cancer in developed nations can be attributed to dietary habits, smoking, a sedentary lifestyle and obesity. Several treatment regimens are available for primary and metastatic colorectal cancer; however, these treatment options have had limited impact on cure and disease-free survival, and novel agents need to be developed for treating colorectal cancer. Thus, the objective of this study was to explore the anticancer mechanism of a benzo(1,3)dioxol-based derivative of sulfonamide. The compound's inhibitory effect on cell proliferation was determined using the MTT assay and the xCelligence RTDP machine. Alternations in the expression of Bcl-2 and inhibitor of apoptosis protein families were detected by western blotting. Apoptotic marker protein expression, including cytochrome c and cleaved poly(ADP-ribose)polymerase was measured in the cytosolic extract of cells. Apoptosis and necrosis were detected by flow cytometry and immunofluorescence. Reactive oxygen species (ROS), and activation of caspase-3 and caspase-7 were measured using flow cytometry. Activation of the JNK pathway was detected by western blotting. We investigated the molecular mechanism of action of the sulfonamide derivative on colorectal cancer cells and found that the compound possesses a potent anticancer effect, which is primarily exerted by inducing apoptosis and necrosis. Interestingly, this compound exhibited little antiproliferative effect against the normal colonic epithelial cell line FHC. Furthermore, our results showed that the compound could significantly increase ROS production. Apoptosis induction could be attenuated by the free oxygen radical scavenger N-acetyl cysteine (NAC), indicating that the antiproliferative effect of this compound on colorectal cancer cells is at least partially dependent on the redox balance. In addition, JNK signaling was activated by treatment with this derivative, which led to the induction of apoptosis. On the contrary, a JNK inhibitor could suppress the cell death induced by this compound. Our findings thus suggested a novel anticancer mechanism of a benzo(1,3)dioxol-based derivative of sulfonamide for colorectal cancer cells and may have therapeutic potential for the treatment of colorectal cancer; however, further investigation is required.

Introduction

In 2018, colorectal cancer (CRC) accounted for 1.6 million cancer-associated mortalities worldwide (1). CRC is the third major cause of mortality due to cancer in both males and females in the United States of America (1). Furthermore, it is the most common cancer among men and the third most common among women in Saudi Arabia (2). A low incidence of CRC was reported until a few decades ago; however, recently, it has become widespread, accounting for ~10% of cancer-associated mortalities in developed countries (3). Its emergence can be attributed to population aging, along with dietary habits and other risk factors, such as smoking, a sedentary lifestyle and obesity (3). Novel treatment options available for CRC include laparoscopic surgery, radiotherapy, and chemotherapy; however, the effectiveness of these treatment options on long-term disease-free survival is limited (3). Therefore, there is an urgent need to develop therapeutic treatments for CRC, specifically metastatic CRC.
Oxidative stress plays an essential role in a number of physiological and pathological processes (4). A certain level of reactive oxygen species (ROS) is essential for normal cellular homeostasis (4). ROS accumulation can have a dual effect, which mainly depends on the concentration of ROS, the origin of the cancer and the activation of cellular signaling during tumorigenesis (4). A moderate level of ROS leads to cell damage, mutation and inflammation, resulting in tumor initiation and progression; however, excessive ROS accumulation in cancer cells leads to cell death via apoptosis, necrosis and autophagy (4). ROS levels are generally higher in cancer cells than in normal cells (4). Under these circumstances, cancer cells are more vulnerable to attack by excessive ROS from an exogenous source (5-7). Mitogen-activated protein kinases (Erk, p38, and JNK) serve a central role in ROS-mediated apoptotic signaling (8). Many studies have reported that ROS mediate cell death by regulating the JNK and p38 MAPK pathways (8-10).

In the present study, we assessed the molecular mechanism underlying the anticancer effects of the sulfonamide derivative (4-((2-(benzo[d][1,3]dioxol-5-yl)quinazolin-4-yl)amino)benzenesulfonamide), 3G, on human CRC cell lines.

Materials and methods

Cell culture. HT-29 and SW620 cell lines were purchased from the American Type Culture Collection and maintained in Roswell Park Memorial Institute medium-1640 (RPMI-1640; Thermo Fisher Scientific, Inc.) containing 10% heat-inactivated fetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc.), 100 μg/ml streptomycin (Invitrogen; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin (Invitrogen; Thermo Fisher Scientific, Waltham MA, USA), and 2 mM L-glutamine (Invitrogen; Thermo Fisher Scientific, Inc.). FHC, normal colon epithelial cells (a gift from Dr Mohammad Azhar Aziz, KAIMRC), were grown in Dulbecco’s modified Eagle’s medium: F-12 (Invitrogen; Thermo Fisher Scientific, Inc.) with 10% heat-inactivated fetal bovine serum (Invitrogen; Thermo Fisher Scientific, Inc.); 100 μg/ml streptomycin (Invitrogen; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin (Invitrogen; Thermo Fisher Scientific, Inc.), 2 mM L-glutamine (Invitrogen; Thermo Fisher Scientific, Inc.), 10 ng/ml cholera toxin (Thermo Fisher Scientific, Inc.), 0.005 mg/ml insulin (Thermo Fisher Scientific, Inc.), 0.005 mg/ml transferrin (Thermo Fisher Scientific, Inc.), and 100 ng/ml hydrocortisone (Thermo Fisher Scientific, Inc.). 3G, a sulfonamide derivative, was dissolved in dimethyl sulfoxide (DMSO) and a 10 mM stock solution was prepared and stored at -20°C. Control cells were treated with dMSO. In certain experiments, N-acetylcysteine (NAC, 5 mM, Santa Cruz Biotechnology, Inc.) and the JNK inhibitor SP600125 (10 μM, Santa Cruz Biotechnology, Inc.) were used.

Cell proliferation assay. Cell proliferation was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay (11). Briefly, the cells were cultured in 96-well plates at 37°C for 24 h; they were treated with different concentrations (2.5, 5, 10, 15, 20, 30 and 40 μM of 3G for 24 h. 10 μl of freshly prepared MTT solution (5 mM) was added to the cells and further incubation was performed for 2 h at 37°C in 5% CO2. Thereafter, DMSO was added to solubilize the formazan crystals. The optical density was read at 540 nm using a microplate reader. The mean and standard deviation values of three independent experiments were determined. Western blotting. 3G-treated cells and control cells were harvested and total lysates were prepared using radioimmunoprecipitation assay lysis buffer (Boston BioProducts) as previously described (13). Briefly, harvested cell pellets were dissolved in cell lysis buffer (Boston BioProducts), incubated on ice for 15 min, and centrifuged at 10,000 x g
at 4°C for 15 min. Supernatant containing soluble proteins was collected and protein concentrations were determined using the Bradford protein reagent (Bio-Rad Laboratories Inc.). Equal amounts (20 µg) of proteins were electrophoresed on 4-20% Mini-Protein TGX precast gels (cat. no. 456-1094; Bio-Rad Laboratories Inc.). Proteins were transferred to nitrocellulose trans-blot turbo membranes (0.2 µm) via the trans-blot turbo transfer system (Bio-Rad Laboratories Inc.). The membranes were blocked with 5% blotting-grade blocker in PBS containing 0.1% Tween-20 (PBST) for 1 h at 25°C. The membranes were exposed overnight to the following primary antibodies at 4°C: Anti-cytochrome c (1:200; Abcam, ab65311), anti-p53 (Santa Cruz Biotechnology Inc., sc-99), anti-Bcl-2-associated X protein (Bax; Santa Cruz Biotechnology Inc., sc-70408), anti-Bcl2 (Santa Cruz Biotechnology Inc., sc-492), anti-Bcl-extra-large (Bcl-xL; Santa Cruz Biotechnology Inc., sc-56021), anti-cyclin D1 (Santa Cruz Biotechnology Inc., sc-8396), anti-survivin (Santa Cruz Biotechnology Inc., sc-101433), anti-X-linked inhibitor of apoptosis protein (XIAP; Santa Cruz Biotechnology Inc., sc-58537), anti-poly(ADP-ribose)polymerase (PARP, cleaved; Biovision, cat. no. 3140-100), anti-cyclin E1 (Santa Cruz Biotechnology Inc., sc-248), anti-p21 (Santa Cruz Biotechnology Inc., sc-397), and anti-β-actin (1:10,000; Santa Cruz Biotechnology Inc., sc-47778), anti-phosphorylated (P)‑JNK (cat. no. 9251, Cell Signaling Technology Inc.), anti-c-Jun (cat. no. 3270, Cell Signaling Technology, Inc.), and P-activating transcription factor 2 (ATF2; cat. no. 24329, Cell Signaling Technology, Inc.), anti-JNK (Santa Cruz Biotechnology Inc., sc-7345), anti-c-Jun (Santa Cruz Biotechnology Inc., sc-74543) and anti-ATF2 (Santa Cruz Biotechnology Inc., sc-242) antibodies. The membranes were washed with twice with PBST and once with PBS and incubated with HRP-conjugated mouse (sc-51602) and HRP-conjugated rabbit (sc-2357) secondary antibodies (1:3,000; Santa Cruz Biotechnology Inc.) at room temperature for 1 h. Reactivity was detected by chemiluminescence using the Clarity Western ECL substrate (Bio-Rad Laboratories Inc.). Chemiluminescence was detected using a blot scanner (LI-COR) and densitometry analysis was done using Image Studio digits Ver 3.1 (LI-COR Biosciences).

Cytochrome c measurement. Cytosolic extracts were prepared from control and 3G-treated cells by using cytosolic extraction buffer (Invitrogen Thermo Fisher Scientific, Inc.) and centrifugation at 10,000 x g at 4°C for 10 min. Subsequently, the cytosolic extracts were immunoblotted for cytochrome c as aforementioned.

ROS measurement by flow cytometry. Cells were cultured to 60-70% confluency and treated with 3G for 24 h. Thereafter, they were harvested by trypsinization. All cells were incubated with 1.0 µM 2,7’-dichlorodihydrofluorescein diacetate (DCF-DA) for 15 min at 37°C. They were then washed twice with PBS and analyzed with a flow cytometer (BD FACSCalibur; CellQuest Pro Version 6.0, BD Biosciences) for ROS detection using a 488 nm laser for excitation and detected at 535 nm (FL1 channel).

Caspase-3 and caspase-7 detection by flow cytometry. The HT29 cell line was cultured and treated with 3G for 24 h. To measure the activation of the caspase cascade, we used the Vybrant™ FAM Caspase-3 and Caspase-7 assay kit (Invitrogen; Thermo Fisher Scientific, Inc.). Briefly, the cells were stained with FLICA reagent and incubated for 60 min at 37°C under 5% CO₂. Then, the cells were washed twice with washing buffer followed by the addition of PI and incubation for 5-10 min at room temperature. The stained cells were analyzed using BD FACSCalibur (CellQuest Pro Version 6.0) with excitation at 488 nm and green emission for the FLICA-stained cells (FL1) or red emission for PI (FL3).

Statistical analysis. All the experiments were performed in triplicate and the results were expressed as mean of three independent experiments (mean ± standard deviation). Statistical analyses were performed using GraphPad Prism 7 (GraphPad Software Inc.). The mean values between the control and treated groups were compared using a two-tailed Student's t-test and one-way analysis of variance followed by a Tukey's post hoc test. P<0.05 was considered to indicate a statistically significant difference.

Results

3G inhibits cell proliferation. To determine the cytotoxic activity of 3G (Fig. 1A), the human adenoma CRC cell line HT-29 was treated with different concentrations of 3G. As expected, 3G inhibited the viability of HT-29 cells in a dose-dependent manner (Fig. 1B). A similar finding was observed in the metastatic CRC cell line SW620 (Fig. 1C). 3G treatment of normal colon epithelial cells, FHC, resulted in little inhibition of cell viability (Fig. 1D). To confirm these findings, we employed another technique, real-time measurement of cell proliferation by using the xCelligence RTDP machine. To this end, HT-29 cells were cultured in an E-plate for 24 h and then treated with different concentrations of 3G. We found that 3G inhibited cell viability in a time- and dose-dependent manner (Fig. 2A). Similarly, 3G also inhibited the viability of the metastatic CRC cell line SW620 in a dose-dependent manner as compared with the control (Fig. 2B). Both the techniques work on different principles. MTT is an end point method; however, xCelligence RTDP analysis determines cell proliferation by measuring the cellular impedance in real time. Both the methodologies were found to indicate a similar trend of inhibited cell proliferation by 3G. These findings demonstrated that 3G effectively inhibited the viability of different CRC cell lines with no or little effect on normal cells.

3G modulates p53, Bcl2, and IAP family protein expression. P53 is a well-known tumor suppressor gene controlling cellular homeostasis (14). HT-29 cells treated with 3G demonstrated upregulated p53 expression (Fig. 3A). Treatment of the metastatic CRC cell line SW620 with 3G also resulted in increased p53 expression (Fig. 3B). The Bcl2 family of proteins is known to regulate cell proliferation and apoptosis. The balance between proapoptotic and antiapoptotic protein expression determines cell fate under stress (15). The treatment of HT-29 cells with different concentrations of 3G resulted in the elevated expression of Bax, and inhibition of Bcl2 and Bcl-xL (Fig. 3A). A similar result was obtained in SW620 cells (Fig. 3B). The
Figure 1. 3G inhibits cell proliferation. (A) Structure of 3G. (B and C) HT-29 and SW620 cells were treated with different concentrations of 3G as indicated. Cell proliferation was measured by the MTT assay. (D) The normal colon epithelial cell line, FHC, was treated with different concentrations of 3G for 24 h. Cell proliferation was determined using the MTT assay and the results were expressed the mean ± standard deviation of three experiments.

Figure 2. 3G inhibits real-time cell proliferation. (A) 5,000 HT-29 cells were seeded in a 16-well E-plate for 24 h. The next day, the cells were treated with different concentrations of 3G. Real-time cell proliferation of HT-29 cells was evaluated by measuring cell indexes to assess the cytotoxic effect of 3G by using the xCELLigence RTCA-dP system. (B) SW620 cells (12,000 cells/well) were seeded in an E-plate. After 24 h, the cells were treated with different concentrations of 3G. Real-time cell proliferation was determined by measuring cell indexes in the control and 3G-treated cells.
cell cycle serves a critical role in cellular transformation and tumor progression. Cyclins are known to regulate the cell cycle in tumorigenesis (16). 3G-treated HT-29 cells exhibited down-regulated cyclin D1 expression in a dose-dependent manner (Fig. 3A). 3G treatment of SW620 cells resulted in the depletion of cyclin D1 expression without notable alterations in that of cyclin E1 (Fig. 3B). Survivin and XIAP belong to the IAP family of proteins, and are known to inhibit caspase activation, thereby negatively regulating apoptosis in the process of programmed cell death (17). 3G inhibited survivin and XIAP protein expression in HT-29 and SW620 cells (Fig. 3A and B).

3G activates PARP and cytochrome c release. During cellular stress, the ratio of proapoptotic to antiapoptotic proteins determines whether the cells undergo cell death (15). Inhibition of Bcl2 and Bcl-xL releases Bax, which forms oligomers, resulting in the alteration of the outer mitochondrial membrane potential and leads to the release of cytochrome c into the cytosol (18). Cells undergoing stress experience PARP activation by cleavage, leading to ATP depletion and thereby cell lysis (18). In this study, 3G was found to activate PARP and induce cytochrome c release in the cytosolic fraction in HT29 (Fig. 3C) and SW620 cells (Fig. 3D).

3G induces apoptosis and necrosis. We investigated whether 3G could induce cell death in CRC cell lines. To this end, HT-29 cells were treated with 3G for 24 h and then stained with Annexin V and PI. 3G treatment for 24 h increased the percentage of cell death, from 5.9% in the control to 38%, which comprised apoptotic (12.4%) and necrotic cells (25.6%; Fig. 4A). These findings were confirmed by staining 3G-treated cells with apopxin and 7-ADD by using immunofluorescence. 3G-treated HT-29 cells stained positive with apopxin and 7-ADD, indicating cell death (Fig. 4B). 3G treatment of SW620

Figure 3. 3G modulates p53, Bcl2 and IAP family protein expression. (A and B) HT-29 and SW620 cells were treated with different concentrations of 3G for 24 h. Cell lysates were immunoblotted with appropriate antibodies. (C and D) HT-29 and SW620 cells treated with 3G for 24 h. Cytosolic extracts were prepared and immunoblotted with the indicated antibodies. Bcl-xL, Bcl-2-extra large; Bax, Bcl-2-associated X protein; PARP, poly(ADP-ribose)polymerase; XIAP, X-linked inhibitor of apoptosis protein.
Figure 4. 3G induces apoptosis and necrosis. (A) HT-29 cells were treated with 3G (20 µM) for 24 h. Total cell death, including apoptosis and necrosis, was measured by Annexin V/PI staining by using flow cytometry. Results shown are representative of three independent experiments. *P<0.05, **P<0.01 vs. control; (B) HT-29 cells were treated with 3G for 24 h, and then incubated with the green Apopxin solution and 7-ADD and green fluorescence (Excitation/Emission=490/525 nm) was measured by fluorescence microscopy vs. the 7AAD and DAPI stains (for whole cell content visualization). Magnification, x20. (C) SW620 cells were treated with 3G for 24 h. Total cell death comprising apoptosis and necrosis was measured using Annexin V/PI staining by flow cytometry. The results shown are representative of three independent experiments. *P<0.01 vs. control.
cells resulted in 7.3% apoptosis as compared with 3.1% in control cells. Additionally, 3G-treated SW620 cells exhibited a significant increase in necrosis to 39.99% compared with only 2.79% in the control cells (Fig. 4C). Thus, these findings indicate that 3G induced cell death via both apoptosis and necrosis.

3G induces ROS-mediated cell death. To determine whether 3G has any effect on ROS production in CRC cell lines and whether the induction of 3G-induced cell death is mediated by ROS, we used a fluorescent probe (DCF-DA) to monitor the intracellular ROS generation in control and 3G-treated cells. As shown in Fig. 5A, 3G-treated cells demonstrated notably higher ROS production than control cells as indicated by a right shift of the peak. NAc is a common antioxidant; pretreatment with NAc resulted in a decrease in ROS levels (Fig. 5A). Similarly, 3G-treated SW620 cells exhibited elevated ROS levels; however, pretreatment with NAC resulted in suppressed ROS generation (Fig. 5B). To determine whether 3G-induced cell death is mediated by ROS production, we evaluated 3G-induced apoptosis in cells pretreated with NAC, a ROS scavenger. SW620 cells were pretreated with or without NAC (5 mM) for 1 h and were then subjected to 3G treatment for 24 h. As expected, pretreatment of cells with NAC induced a significant decrease in ROS-mediated apoptosis when compared 3G treatment alone (Fig. 5C). These data suggest that 3G-induced apoptosis and necrosis in CRC cells may be mediated by elevated ROS production.

3G activates the JNK pathway. Several anticancer agents induce ROS generation and activate the MAPK signaling pathway, resulting in the induction of cell death (19,20). In the present study, we determined the JNK phosphorylation status. HT-29 cells treated with different concentrations of 3G exhibited increased phosphorylation of JNK, and downstream target substrates cJun and ATF2, indicating that 3G activated this pathway (Fig. 6A-C). The activation of JNK in SW620 cells exposed to 3G for 24 h was evaluated by immunoblotting. The phosphorylation of JNK increased after 3G treatment. To confirm the activation of the JNK pathway, its downstream effectors were evaluated. SW620 cells treated with 3G exhibited increased phosphorylation of downstream target substrates of the JNK pathway, such as cJun and ATF2 (Fig. 6B-D). We used the JNK inhibitor SP600125 to confirm our findings. HT-29 cells were pretreated with SP600125 and then 3G for 24 h, after which caspase-3/7 activation was measured. The JNK inhibitor alleviated the 3G-induced caspase-3/7 activation, confirming that 3G-induced cell death is likely to be mediated by JNK activation (Fig. 7A). Similarly, it inhibited the 3G-induced PARP cleavage and cytochrome c release (Fig. 7B-E). These findings thus demonstrate that 3G-induced cell death may be mediated by ROS generation and JNK pathway activation.
Discussion

Sulfonamide and several of its derivatives have been reported to have potential as anticancer agents for application in the treatment of various cancers. Liu et al (21) showed that para-toluenesulfonamide induced cell death in tongue squamous cell cancer. Saha et al (22) revealed the apoptosis-inducing activity of bis(sulfonamide) in HeLa cells. The trans-sulfonamide-platinum complex was reported to induce anti-tumor activity against melanoma cancer cell lines (23). Our previous findings have shown that certain novel derivatives of sulfonamide possess anticancer activity (11-13). In the present study, we evaluated the antiproliferative effects of 3G in human CRC cell lines.
3G exhibited cytotoxicity in a dose- and time-dependent manner in adenocarcinoma (HT-29) and metastatic CRC cells (SW620). Cellular transformation in these cell lines occurs with a mutation in the tumor suppressor gene and activation of tumor initiation (24).

p53 is a well-known tumor suppressor gene; it undergoes mutation, thereby initiating uncontrolled cell proliferation. 3G treatment resulted in a dose-dependent increase in p53 protein expression in the present study. The Bcl2 family of proteins constitutes proapoptotic (Bax, Bad and Bak) and antiapoptotic (Bcl2, Bcl-xL, and myeloid leukemia cell differentiation protein 1) proteins, which controls cell death under conditions of stress (15). Bcl2 and Bcl-xL expression inhibits apoptosis and promotes cell survival (25). Aberrant expression of Bcl2 is indicative of an early event in colorectal carcinogenesis that can block apoptosis (26). The antiapoptotic protein Bcl-xL has been identified as a driver of colorectal carcinogenesis, thus making it a target for cancer therapeutics (27). In this study, we found that 3G inhibited Bcl2 and Bcl-xL protein expression in human CRC cell lines. Therefore, the induction of p53, and depletion of Bcl2 and Bcl-xL protein expression suggest a mechanism of action for 3G-mediated inhibition of cell proliferation. Cyclin D1 serves an important role in cellular proliferation and its aberrant regulation has been linked to colorectal tumorigenesis (28). The sulfonamide derivative 3G inhibited cyclin D1 expression in HT-29 and SW620 cells. XIAP and survivin belong to the IAP family of proteins, which have been shown to be significantly correlated with colorectal tumorigenesis (29,30). Importantly, 3G inhibited XIAP and survivin protein expression in CRC cells.

We reported that 3G could trigger a significant increase in apoptosis and necrosis in CRC cells. Importantly, ROS levels in HT-29 and SW620 cells were significantly elevated by 3G treatment. Previous reports have suggested that some small-molecule and natural products possess pro-oxidant properties (31-33). We have determined that certain derivatives of sulfonamide induce ROS production (12,13). Treating cells with natural products, such as curcumin and resveratrol, resulted in pro-oxidant and antioxidant effects, depending on the concentrations of the compounds used (34,35). The antioxidant NAC could significantly attenuate 3G-induced apoptosis in CRC cells in our study. Generally, tumor cells have higher levels of ROS and cannot tolerate further ROS insults (36). MAPK-like JNK and p38 kinase are known as stress-activated protein kinases (37). Certain studies have previously reported that p38 MAPK and JNK activation plays a critical role in sulfonamide derivative-induced cellular apoptosis (38,39). Consistent with this finding, another sulfonamide derivative has shown similar effects on CRC cells (40). Furthermore, we reported that 3G induced a significant increase in the phosphorylation of JNK in a dose-dependent manner. In addition, 3G-induced activation of JNK further phosphorylated its downstream target substrates, including cJun and ATF2. These findings demonstrated that 3G indeed activates the JNK pathway in CRC cells. Therefore, the mutual augmentation of JNK activation and ROS production in 3G-induced cell death may be key in the mechanism underlying the effects of 3G. In summary, our results suggested that 3G could efficiently induce ROS-mediated cell death in human CRC cells. The cytotoxic effects of 3G could be mediated by the induction of
ROS generation and activation of the JNK pathway. Therefore, our findings indicate that 3G may have potential as an anti-tumor agent for the treatment of CRC. Further investigation is required to determine its effects in animal models and in combination therapy.

Acknowledgements

The authors are grateful to the Deanship of Scientific Research, King Saud University, for funding through the Vice Deanship of Scientific Research Chairs. The authors thank the Investigator support unit at King Saud University for technical support.

Funding

The authors are grateful to the Deanship of Scientific Research, King Saud University, for funding through the Vice Deanship of Scientific Research Chairs.

Availability of data and materials

All data generated are included in this research paper.

Authors' contributions

Conception and design of experiments: RA, MAVM, and ME; acquisition of data: MAVM, ME, and WME; analysis and interpretation of data: RA, OAO, KAK, AA, and HAA; drafting of manuscript: RA, MA, AA, HAAA, and WME; critical reading and revision: RA, MAVM, ME, AA, and MA. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interest

All authors declare that they have no competing interest related to this work.

References